Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-05-12

Clinical Trial Update: Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Trial [Phase 4]

View source ↗

Summary

A 48-week Phase 4 trial comparing golimumab versus pamidronate for axial spondyloarthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Aredia (pamidronate disodium)
  • Simponi (golimumab)

Snippet

Sponsor: Tuen Mun Hospital | Conditions: Spondyloarthropathy | Phase 4 | Status: COMPLETED